Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Introduction to Hemostasis01:05

Introduction to Hemostasis

14.2K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
14.2K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

10.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.9K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BACT-URIE: A Novel Score Integrating Bacteriuria to Predict Infective Endocarditis in Patients With <i>Staphylococcus aureus</i> Bacteremia.

Open forum infectious diseases·2026
Same author

Protein-level profiling of TIGIT axis components in human PDAC reveals immune-suppressive expression patterns.

Cancer immunology, immunotherapy : CII·2026
Same author

Hereditary angioedema (HAE) in Belgium: results from a national survey.

Frontiers in allergy·2023
Same author

Clinical practice of hereditary angioedema in Belgium: opportunities for optimized care.

Acta clinica Belgica·2023
Same author

[Rare manifestations of monoclonal gammopathies: About two clinical cases and literature review].

La Revue de medecine interne·2023
Same author

European principles of inhibitor management in patients with haemophilia: implications of new treatment options.

Orphanet journal of rare diseases·2020

Related Experiment Video

Updated: Apr 30, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

174

Novel products for haemostasis.

M Shima1, C Hermans, P de Moerloose

  • 1Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|April 26, 2014
PubMed
Summary
This summary is machine-generated.

Novel bypassing agents ACE910 and MC710 show promise for hemophilia treatment, addressing inhibitor development and high costs. Research also explores biosimil products and treatments for rare bleeding disorders.

Keywords:
biosimilarsbispecific antibodybypassing therapyhaemophiliarare bleeding disorders (RBDs)

More Related Videos

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

9.1K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K

Related Experiment Videos

Last Updated: Apr 30, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

174
Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

9.1K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K

Area of Science:

  • Hematology
  • Pharmacology
  • Biotechnology

Background:

  • Development of inhibitors is a major challenge in hemophilia treatment.
  • Current treatments for hemophilia and rare bleeding disorders can be costly and carry risks.
  • There is a need for innovative and cost-effective therapeutic options.

Purpose of the Study:

  • To evaluate novel bypassing agents for hemophilia treatment, focusing on inhibitor patients.
  • To explore the potential of biosimilar products to reduce treatment costs.
  • To review advancements in treating rare bleeding disorders.

Main Methods:

  • Phase 1 clinical trial of ACE910, a humanized bispecific antibody.
  • Preclinical and clinical studies (Phase I/II) of MC710, a mixture of FVIIa and FX.
  • Review of regulatory and economic factors for biosimilar adoption.
  • Assessment of new treatments for rare bleeding disorders, including recombinant FXIIIa.

Main Results:

  • ACE910 demonstrated acceptable safety and tolerability in healthy adults.
  • MC710 showed comparable or superior pharmacokinetic, pharmacodynamic, efficacy, and safety profiles to conventional agents.
  • Biosimilar products present a potentially less expensive alternative but face regulatory hurdles.
  • New specific plasma-derived and recombinant products are becoming available for rare bleeding disorders, with positive results for recombinant FXIIIa.

Conclusions:

  • ACE910 and MC710 represent promising advancements in hemophilia treatment, particularly for inhibitor patients.
  • Biosimil products could offer cost-saving benefits if regulatory and acceptance issues are addressed.
  • The landscape for treating rare bleeding disorders is improving with targeted therapies.